Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province, PR China.
Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province, PR China.
J Control Release. 2022 Feb;342:280-294. doi: 10.1016/j.jconrel.2022.01.010. Epub 2022 Jan 10.
Malignant tumor is still a leading threat to human health. Despite the rapid development of targeted therapeutic strategies, any treatment specifically acting on single target would inevitably suffer from tumor resistance, largely due to the genetic instability and variability of tumor cells. Thus, traditional therapies such as broad-spectrum chemotherapy would certainly occupy an important position in clinical cancer therapy. Nevertheless, most chemotherapeutic drugs have long been criticized for unsatisfactory therapeutic efficacy with severe off-target toxicity. Although several chemotherapeutic nanomedicines with improved therapeutic safety have been applied in clinics, the therapeutic outcomes still do not fulfill expectation. To address this challenge, enormous efforts have been devoted to developing novel nano-formulations for efficient delivery of chemotherapeutic drugs. Herein, we aim to outline the latest progression in the emerging nanomedicines of paclitaxel (PTX), with special attention to the functional nanocarriers, self-delivering prodrug-nanoassemblies and combination nanotherapeutics of PTX. Finally, the challenges and opportunities of these functional PTX nanomedicines in clinical translation are spotlighted.
恶性肿瘤仍然是人类健康的主要威胁。尽管靶向治疗策略发展迅速，但任何专门针对单一靶点的治疗方法都不可避免地会受到肿瘤耐药性的影响，这主要是由于肿瘤细胞的遗传不稳定性和可变性。因此，传统的治疗方法，如广谱化疗，在临床癌症治疗中肯定会占据重要地位。然而，长期以来，大多数化疗药物因其治疗效果不理想且具有严重的脱靶毒性而受到批评。尽管一些具有改善治疗安全性的化疗纳米药物已应用于临床，但治疗效果仍未达到预期。为了解决这一挑战，人们投入了大量精力来开发新型纳米制剂，以有效输送化疗药物。在此，我们旨在概述紫杉醇（PTX）新兴纳米药物的最新进展，特别关注 PTX 的功能纳米载体、自递送前药纳米组装体和联合纳米治疗剂。最后，重点介绍了这些功能性 PTX 纳米药物在临床转化中的挑战和机遇。
